NASDAQ:NTEC - Intec Pharma Stock Price, Price Target & More

$5.10 -0.05 (-0.97 %)
(As of 04/25/2018 08:54 AM ET)
Previous Close$5.15
Today's Range$5.05 - $5.35
52-Week Range$4.80 - $9.80
Volume206,400 shs
Average Volume194,786 shs
Market Capitalization$169.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26

About Intec Pharma (NASDAQ:NTEC)

Intec Pharma logoIntec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for NTEC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NTEC
CUSIPN/A
Phone972-2586-4657

Debt

Debt-to-Equity RatioN/A
Current Ratio9.82%
Quick Ratio9.82%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.26 per share
Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees70
Outstanding Shares32,830,000

How to Become a New Pot Stock Millionaire

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd. (NASDAQ:NTEC) issued its earnings results on Friday, March, 9th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.19. View Intec Pharma's Earnings History.

When is Intec Pharma's next earnings date?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Friday, June, 8th 2018. View Earnings Estimates for Intec Pharma.

What price target have analysts set for NTEC?

6 brokers have issued 12 month price objectives for Intec Pharma's shares. Their forecasts range from $10.00 to $16.00. On average, they expect Intec Pharma's stock price to reach $13.60 in the next year. View Analyst Ratings for Intec Pharma.

What are Wall Street analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:
  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (3/16/2018)
  • 2. Maxim Group analysts commented, "Intec reported 3Q17 with a net loss of $7.7M and ended the period with $63.0M in cash, including proceeds from a $57.5M equity financing. At the current burn rate, we estimate the company has runway into late 2019." (11/17/2017)

Are investors shorting Intec Pharma?

Intec Pharma saw a decline in short interest in April. As of April 13th, there was short interest totalling 263,662 shares, a decline of 47.6% from the March 30th total of 503,544 shares. Based on an average trading volume of 459,043 shares, the short-interest ratio is currently 0.6 days. Currently, 1.0% of the shares of the stock are short sold.

Who are some of Intec Pharma's key competitors?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:
  • Mr. Nir Sassi, Chief Financial Officer (Age 42)
  • Dr. Nadav Navon Ph.D., Chief Operating Officer (Age 49)
  • Mr. Zeev Weiss, Clinical and Bus. Devel. Consultant (Age 56)
  • Mr. Jeffrey A. Meckler, Vice Chairman & CEO (Age 51)
  • Mr. Walt Addison Linscott Esq., Chief Admin. Officer (Age 57)

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

Has Intec Pharma been receiving favorable news coverage?

News coverage about NTEC stock has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Intec Pharma earned a media sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Intec Pharma?

Shares of NTEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of NTEC stock can currently be purchased for approximately $5.10.

How big of a company is Intec Pharma?

Intec Pharma has a market capitalization of $169.05 million. The biotechnology company earns $-29,090,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Intec Pharma employs 70 workers across the globe.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 Hartom Street Har Hotzvim, Jerusalem L3, 9777512. The biotechnology company can be reached via phone at 972-2586-4657 or via email at [email protected]


MarketBeat Community Rating for Intec Pharma (NTEC)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  143 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe NTEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTEC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intec Pharma (NASDAQ:NTEC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Intec Pharma in the last 12 months. Their average twelve-month price target is $13.60, suggesting that the stock has a possible upside of 166.67%. The high price target for NTEC is $16.00 and the low price target for NTEC is $10.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.60$13.60$12.00$12.25
Price Target Upside: 166.67% upside114.17% upside142.42% upside44.12% upside

Intec Pharma (NASDAQ:NTEC) Consensus Price Target History

Price Target History for Intec Pharma (NASDAQ:NTEC)

Intec Pharma (NASDAQ:NTEC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2018OppenheimerSet Price TargetBuy$15.00LowView Rating Details
3/26/2018Maxim GroupBoost Price TargetBuy -> Buy$8.00 -> $12.00MediumView Rating Details
3/18/2018HC WainwrightSet Price TargetBuy$16.00LowView Rating Details
2/28/2018Ladenburg ThalmannInitiated CoverageBuy -> BuyMediumView Rating Details
9/21/2017CIBCReiterated RatingOutperform -> Outperform$10.00 -> $15.00MediumView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$10.00HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Intec Pharma (NASDAQ:NTEC) Earnings History and Estimates Chart

Earnings by Quarter for Intec Pharma (NASDAQ:NTEC)

Intec Pharma (NASDAQ:NTEC) Earnings Estimates

2018 EPS Consensus Estimate: ($1.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.27)($0.27)($0.27)
Q2 20181($0.30)($0.30)($0.30)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.34)($0.34)($0.34)

Intec Pharma (NASDAQ NTEC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/8/2018        
3/9/2018Q4 2017($0.20)($0.39)ViewN/AView Earnings Details
11/15/2017Q3 2017($0.34)($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.47)ViewN/AView Earnings Details
4/7/2017Q4 2016($0.32)ViewN/AView Earnings Details
9/1/2016Q2 2016($0.37)($0.18)ViewN/AView Earnings Details
3/14/2016Q4 2015($0.10)($0.29)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.07)($0.16)ViewN/AView Earnings Details
8/31/2015Q2 2015($0.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Intec Pharma (NASDAQ:NTEC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Intec Pharma (NASDAQ NTEC) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 32.88%
Insider Trading History for Intec Pharma (NASDAQ:NTEC)
Institutional Ownership by Quarter for Intec Pharma (NASDAQ:NTEC)

Intec Pharma (NASDAQ NTEC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Intec Pharma (NASDAQ NTEC) News Headlines

Source:
DateHeadline
Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual MeetingIntec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting
finance.yahoo.com - April 24 at 8:15 AM
-$0.28 Earnings Per Share Expected for Intec Pharma Ltd. (NTEC) This Quarter-$0.28 Earnings Per Share Expected for Intec Pharma Ltd. (NTEC) This Quarter
www.americanbankingnews.com - April 21 at 9:06 PM
Intec Pharma closes $35M equity offeringIntec Pharma closes $35M equity offering
seekingalpha.com - April 13 at 5:37 PM
In Biopharma M&A, Where Theres Real Innovation Theres Someone Willing to PayIn Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'
www.thestreet.com - April 13 at 5:37 PM
Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary SharesIntec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares
finance.yahoo.com - April 13 at 5:37 PM
Oppenheimer Reiterates "$15.00" Price Target for Intec Pharma (NTEC)Oppenheimer Reiterates "$15.00" Price Target for Intec Pharma (NTEC)
www.americanbankingnews.com - April 12 at 10:07 AM
Intec Pharma readies stock offeringIntec Pharma readies stock offering
seekingalpha.com - April 11 at 5:37 PM
Intec Rolls Out Stock Offering, Shares Fall HardIntec Rolls Out Stock Offering, Shares Fall Hard
www.baystreet.ca - April 11 at 5:37 PM
Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary SharesIntec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares
finance.yahoo.com - April 11 at 5:37 PM
Intec Pharma (NTEC) Launches Public Offering of Ordinary SharesIntec Pharma (NTEC) Launches Public Offering of Ordinary Shares
www.streetinsider.com - April 11 at 8:24 AM
U.S. STOCKS ON THE MOVE-Intec Pharma, Facebook, Link Motion, MattelU.S. STOCKS ON THE MOVE-Intec Pharma, Facebook, Link Motion, Mattel
www.nasdaq.com - April 11 at 8:24 AM
Roth Capital Analysts Give Intec Pharma (NTEC) a $10.00 Price TargetRoth Capital Analysts Give Intec Pharma (NTEC) a $10.00 Price Target
www.americanbankingnews.com - April 10 at 8:23 PM
Intec Pharma (Nasdaq: NTEC) to Ring The Nasdaq Stock Market Closing BellIntec Pharma (Nasdaq: NTEC) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - April 10 at 5:33 PM
Zacks Investment Research Downgrades Intec Pharma (NTEC) to SellZacks Investment Research Downgrades Intec Pharma (NTEC) to Sell
www.americanbankingnews.com - April 10 at 12:01 PM
Intec Pharma Ltd. (NTEC) Given Average Recommendation of "Buy" by AnalystsIntec Pharma Ltd. (NTEC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 9 at 1:41 AM
Intec Pharma Ltd. (NTEC) Expected to Post Earnings of -$0.28 Per ShareIntec Pharma Ltd. (NTEC) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - April 4 at 11:10 PM
Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual MeetingIntec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting
finance.yahoo.com - April 4 at 8:15 AM
Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinsons DiseaseIntec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease
finance.yahoo.com - April 3 at 8:16 AM
Intec Pharma (NTEC) Downgraded to Hold at Zacks Investment ResearchIntec Pharma (NTEC) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:48 PM
Intec Pharma (NTEC) Given a $12.00 Price Target at Maxim GroupIntec Pharma (NTEC) Given a $12.00 Price Target at Maxim Group
www.americanbankingnews.com - March 26 at 8:36 AM
Form 6-K Intec Pharma Ltd. For: Mar 26Form 6-K Intec Pharma Ltd. For: Mar 26
www.streetinsider.com - March 26 at 8:17 AM
BRIEF-Intec Pharma Appoints Roger Pomerantz To Board Of DirectorsBRIEF-Intec Pharma Appoints Roger Pomerantz To Board Of Directors
www.reuters.com - March 26 at 8:17 AM
Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of DirectorsIntec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors
finance.yahoo.com - March 26 at 8:17 AM
Intec Pharmas (NTEC) Buy Rating Reiterated at OppenheimerIntec Pharma's (NTEC) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - March 21 at 1:56 PM
Intec Pharma (NTEC) Given a $16.00 Price Target at HC WainwrightIntec Pharma (NTEC) Given a $16.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 10:06 PM
-$0.28 EPS Expected for Intec Pharma Ltd (NTEC) This Quarter-$0.28 EPS Expected for Intec Pharma Ltd (NTEC) This Quarter
www.americanbankingnews.com - March 18 at 9:10 PM
Oppenheimer Analysts Give Intec Pharma (NTEC) a $15.00 Price TargetOppenheimer Analysts Give Intec Pharma (NTEC) a $15.00 Price Target
www.americanbankingnews.com - March 18 at 8:48 PM
Intec Pharma (NTEC) Downgraded by Zacks Investment Research to "Sell"Intec Pharma (NTEC) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 17 at 12:04 PM
Intec Pharma Ltd Forecasted to Earn Q1 2018 Earnings of ($0.27) Per Share (NTEC)Intec Pharma Ltd Forecasted to Earn Q1 2018 Earnings of ($0.27) Per Share (NTEC)
www.americanbankingnews.com - March 15 at 6:44 AM
Intec Pharma Ltd (NTEC) Given Average Rating of "Buy" by AnalystsIntec Pharma Ltd (NTEC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 15 at 1:04 AM
Brokers Offer Predictions for Intec Pharma Ltds FY2022 Earnings (NTEC)Brokers Offer Predictions for Intec Pharma Ltd's FY2022 Earnings (NTEC)
www.americanbankingnews.com - March 14 at 4:24 PM
Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinsons DiseaseIntec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease
finance.yahoo.com - March 12 at 6:44 PM
Intec Pharma (NTEC) Stock Rating Reaffirmed by HC WainwrightIntec Pharma (NTEC) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 12 at 2:21 PM
Oppenheimer Reiterates $15.00 Price Target for Intec Pharma (NTEC)Oppenheimer Reiterates $15.00 Price Target for Intec Pharma (NTEC)
www.americanbankingnews.com - March 10 at 8:48 PM
Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business UpdateIntec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
finance.yahoo.com - March 9 at 8:14 AM
Intec Pharma, Ltd. to Present at Four Investor Conferences in MarchIntec Pharma, Ltd. to Present at Four Investor Conferences in March
finance.yahoo.com - March 5 at 8:13 AM
-$0.20 Earnings Per Share Expected for Intec Pharma Ltd (NTEC) This Quarter-$0.20 Earnings Per Share Expected for Intec Pharma Ltd (NTEC) This Quarter
www.americanbankingnews.com - March 1 at 7:09 PM
Intec Pharma (NTEC) Now Covered by Analysts at Ladenburg Thalmann Financial ServicesIntec Pharma (NTEC) Now Covered by Analysts at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - February 28 at 11:22 PM
Intec Pharma (NTEC) Coverage Initiated by Analysts at HC WainwrightIntec Pharma (NTEC) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - February 26 at 2:20 PM
Intec Pharma Ltd (NTEC) Given Consensus Recommendation of "Buy" by AnalystsIntec Pharma Ltd (NTEC) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 18 at 1:30 AM
 Brokerages Expect Intec Pharma Ltd (NTEC) Will Post Earnings of -$0.19 Per Share Brokerages Expect Intec Pharma Ltd (NTEC) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - February 13 at 3:14 AM
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical OfficerIntec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
finance.yahoo.com - January 31 at 9:10 AM
Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.19 Per ShareZacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - January 27 at 5:18 AM
Intec Pharma Ltd (NTEC) Receives Average Rating of "Buy" from AnalystsIntec Pharma Ltd (NTEC) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 24 at 1:44 AM
Critical Review: Proteostasis Therapeutics (PTI) & Intec Pharma (NTEC)Critical Review: Proteostasis Therapeutics (PTI) & Intec Pharma (NTEC)
www.americanbankingnews.com - January 22 at 3:14 PM
Zacks Investment Research Downgrades Intec Pharma (NTEC) to HoldZacks Investment Research Downgrades Intec Pharma (NTEC) to Hold
www.americanbankingnews.com - January 16 at 10:34 AM
Intec Pharma (NTEC) Raised to "Buy" at Zacks Investment ResearchIntec Pharma (NTEC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 9:26 AM
Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.19 Earnings Per ShareZacks: Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - January 10 at 4:04 AM
Intec Pharma (NTEC) Reports Development Collaboration With Global Pharmaceutical CompanyIntec Pharma (NTEC) Reports Development Collaboration With Global Pharmaceutical Company
www.streetinsider.com - January 8 at 5:07 PM
BRIEF-Meitav Dash Investments Ltd Group Reports 7.18 Pct Passive Stake In Intec PharmaBRIEF-Meitav Dash Investments Ltd Group Reports 7.18 Pct Passive Stake In Intec Pharma
www.reuters.com - January 8 at 10:07 AM

SEC Filings

Intec Pharma (NASDAQ:NTEC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intec Pharma (NASDAQ:NTEC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intec Pharma (NASDAQ NTEC) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.